These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38537878)

  • 21. Chimeric antigen receptor therapy meets mRNA technology.
    Wu J; Wu W; Zhou B; Li B
    Trends Biotechnol; 2024 Feb; 42(2):228-240. PubMed ID: 37741706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells.
    Hu D; Yang R; Wang G; Li H; Fan X; Liang G
    Int J Nanomedicine; 2024; 19():2773-2791. PubMed ID: 38525009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
    Irving M; Lanitis E; Migliorini D; Ivics Z; Guedan S
    Hum Gene Ther; 2021 Oct; 32(19-20):1044-1058. PubMed ID: 34662233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
    Salmikangas P; Kinsella N; Chamberlain P
    Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification.
    Yu Q; Zhang M; Chen Y; Chen X; Shi S; Sun K; Ye R; Zheng Y; Chen Y; Xu Y; Peng J
    Int J Nanomedicine; 2020; 15():483-495. PubMed ID: 32158206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR-T Cell Therapy: From the Shop to Cancer Therapy.
    Uscanga-Palomeque AC; Chávez-Escamilla AK; Alvizo-Báez CA; Saavedra-Alonso S; Terrazas-Armendáriz LD; Tamez-Guerra RS; Rodríguez-Padilla C; Alcocer-González JM
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How can Cytokine-induced killer cells overcome CAR-T cell limits.
    Cappuzzello E; Vigolo E; D'Accardio G; Astori G; Rosato A; Sommaggio R
    Front Immunol; 2023; 14():1229540. PubMed ID: 37675107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation.
    Khan AN; Chowdhury A; Karulkar A; Jaiswal AK; Banik A; Asija S; Purwar R
    Front Immunol; 2022; 13():886546. PubMed ID: 35677038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges and new technologies in adoptive cell therapy.
    Zhang P; Zhang G; Wan X
    J Hematol Oncol; 2023 Aug; 16(1):97. PubMed ID: 37596653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for manufacturing cell therapy products aligned with patient needs.
    Guha P; Katz SC
    Methods Cell Biol; 2022; 167():203-226. PubMed ID: 35152997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
    Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
    Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
    Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
    Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.